A global clinical-stage cell-based
therapies and life sciences company
Full Year Results 2019 LEARN MORE
  • 2019 revenues increased nearly 30% year over year
  • Revenue in H2 totalled $13.2m, an increase of 36% over H2 2018 ($9.7m)
  • Delivered 25% revenue CAGR since 2014
  • Gross margins of approximately 88%
May 2020 Fundraise LEARN MORE
  • Oversubscribed fundraise of £25m led by new international
    specialist healthcare crossover
  • Investors Casdin Capital and Sofinnova Partners

MaxCyte is a clinical-stage global cell-based therapies and life sciences company.  As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life.

With 20 of the top 25 and all top 10 pharma as clients

  • Licences granted to 120+ cell therapy programmes, 70+ for clinical use excluding CARMA
  • Blue-chip client base including the top 20 of the top 25 and all of the 10 top global pharma companies
  • Aggregate potential pre-commercial milestones from clinical license deals total more than $800m

Proven track record of revenue growth

  • Consistent ~90% growth margins
  • 5-year revenue CAGR 25%
  • High proportion of recurring revenues providing on-going financial visibility
  • Underlying EBITDA “break-even” achieved in 2019 and expected in 2020

CARMA subsidiary: Unique, novel mRNA-based CAR product for solid tumours

  • First-in-human trial for ovarian cancer and peritoneal mesothelioma; preliminary clinical results expected H2 2020
  • Preparations commenced for CARMA subsidiary to be independently financed by end of 2020

Highlights from the 2019 CMD

Country of Incorporation and Main Country of Operation

The Company’s main country of operation is the United States. The Company is incorporated under the laws of the State of Delaware in the United States. Accordingly, a significant amount of the legislation in England and Wales regulating the operation of companies does not apply to the Company. In addition, the laws of the State of Delaware will apply to the Company, and such laws may provide for mechanisms and procedures that would not otherwise apply to companies incorporated in England and Wales. The rights of Stockholders are subject to the exclusive jurisdiction of the courts of the State of Delaware and are governed by Delaware law and by the Company’s Certificate of Incorporation and Bylaws, which may differ from the typical rights of stockholders in the United Kingdom and other jurisdictions.

The Company is not subject to the provisions of the Takeover Code. Certain provisions have been inserted into the Certificate of Incorporation which adopt similar procedures to the Takeover Code in the event of any party (or parties acting in concert) obtaining 30 per cent. or more of the voting rights attaching to the issued Common Stock, but there is no assurance that the courts of the State of Delaware, US, will uphold or allow the enforcement of these provisions

AIM Securities in Issue

The number of shares in issue is 77,305,169. The percentage of shares not in public hands is 16.5%.

The following lists all disclosed holdings of 3% or larger as of 30 October 2020:

Shareholder Shares Percentage
Casdin Capital (New York) 11,281,334 14.58%
River & Mercantile Asset Mgt (London) 6,849,975 8.85%
Intersouth Partners VI LP (Regional (USA) 5,986,599 7.74%
Sofinnova Partners (Paris) 4,332,289 5.60%
Harbert Mgt (Birmingham) 4,027,572 5.21%
Amati Global Investors (Edinburgh) 3,937,491 5.09%
Canaccord Genuity Wealth Mgt (London) 3,275,350 4.23%
Unicorn Asset Mgt (London) 3,017,857 3.90%
Bost-Jackson (Regional (USA)) 2,455,287 3.17%

The Company currently has two lines of Common Stock admitted to trading on AIM: an unrestricted line of Common Stock trading under the symbol MXCT and a new restricted line of Common Stock under the symbol MXCL which is restricted under Regulation S Category 3 such that purchasers cannot sell or otherwise transfer such Common Stock except pursuant to the requirements of Regulation S until at least the expiry of one year after the closing of the offering which closed on 22 May 2020. There are no other restrictions on the transfer of AIM securities.

Other than the AIM Market of London Stock Exchange plc, the Company has not applied for or agreed to have its securities admitted to or traded on any other exchange or trading platform.


MaxCyte has appointed Panmure Gordon to act as nominated advisor and joint corporate broker to the Company for the purposes of the AIM Rules for Companies.

Panmure Gordon
One New Change
London, EC4M 9AF
United Kingdom

Joint Corporate Broker

Numis Securities Limited
The London Stock Exchange Building
10 Paternoster Square
London EC4M 7LT


CohnReznick LLP
800 Towers Crescent Drive, Suite 1000
Tysons, VA 22182-6213


Link Asset Services
The Registry, 34 Beckenham Road
Beckenham, Kent, BR3 4TU


Travers Smith LLP
10 Snow Hill
London EC1A 2AL

This page was last updated on 30 June 2020.